Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.39) by 2.56 percent. This is unchanged from the same period last year.
Regulus Therapeutics Q4 EPS $(0.40) Misses $(0.39) Estimate
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.